ARTICLES BY LOUIS

• GSK's Discovery Fast Track Contract Starts With Super-Moon Eclipse

  10/30/2015

  “Even the heavenly bodies aligned perfectly. Our partnership with GSK was announced the day of the super-moon total-lunar eclipse.”

       -- Richard Leduc, professor, Department of Pharmacology-Physiology, assistant  vice-dean for knowledge transfer, Université de Sherbrooke, Sherbrooke, Québec

• Who Wants To Work At A CMO Anyways?

  10/23/2015

  Are graduating students and newly trained professionals aware there is an AMRI as well as an Amgen, a Cambrex as well as a Celgene, or a Lonza as well as a Lilly? Even if they are, why would they select the service providers? And why is it positive for for the biotechs and pharma companies if they do?

• Service Provider In “Arbitrage Opportunity Of The Century”

  10/9/2015

  A brand-name outsourcing provider plays a role in an historic “arbitrage opportunity.” “I  truly believe these deals represent the most interesting models – China capital and U.S. technology – for the coming decade,” says  Tiecheng “Alex” Qiao of Ambrx Inc.

• The Paradox In Measuring Your CMO

  10/6/2015

  Something Denise McDade of Capricor Therapeutics said during a session at Outsourced Pharma West stuck in my mind: “Metrics are fundamentally important in measuring and managing any relationship, but there’s a paradox when it comes to outsourcing.”

• Pfizer Says Science First In Alliance Management

  10/2/2015

  Effective alliance managers with an underlying scientific fortitude allow for the growth of outsourcing, without a corresponding growth in the number of alliances, says Pfizer’s Sylvie Sakata.

• Don't Sing The BioPharma Supply-Chain Blues

  9/29/2015

  I’ve got 6 shipments in limbo; 47 days on a tarmac; 58 borders in Europe … And they’re taxing me at every step I take …

• Should You Search Globally For A CMO?

  9/21/2015

  I’m amazed in 2015 just the proposition of searching globally for CMOs is still a difficult decision for biotechs and other drug-developers. But because it is, I’ve captured some comments from industry experts at Outsourced Pharma West that may help.

• New-Era Drug Rx: C-Corp Per Compound And Large Dose Of Outsourcing

  9/14/2015

  Dauntless Pharmaceuticals isn’t the only company with a drug-development model based completely on outsourcing. Dauntless separates itself by where it takes the virtual-biotech model: It establishes a C-Corp for each compound it in-licenses. "From my management style, and viewpoint as a venture capitalist, this is how biotech should be done,” says Joel F. Martin, president and CEO.

• BioPharma Striving For LifeCycle Outsourcing™

  9/8/2015

  I’m usually pretty good at plucking overall themes from the various topics that swirl around international conferences. (Well, at least I think so.) That’s why initially failing to do so for the recent Outsourced Pharma West San Diego (OPW) conference was bothering me.

• Boxes At BMS: Impact Of New Drugs On Packaging Sponsors And Providers

  9/1/2015

  Packaging is transparent to the end-user when done well, but open to criticism from all quarters when done poorly. We can, though, expect an increasing amount of attention all the time. “There are more diverse packaging needs than ever before,” says Dan Marasco, head of Packaging Materials & Device Sourcing at Bristol-Myers Squibb.